+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PharmSource: Contract Manufacturing of Novel In-Licensed Drugs - 2020 Edition

  • PDF Icon


  • 24 Pages
  • February 2020
  • Region: Global
  • GlobalData
  • ID: 5008513
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

PharmSource: Contract Manufacturing of Novel In-Licensed Drugs - 2020 Edition


This expert trend report explores in-licensing trends among FDA New Molecule Entity (NME) approvals 2014-2018, and analyzes how licensing patterns affect propensity to outsource finished dose manufacture. This report is critical for establishing an understanding of the ways bio/pharmaceutical companies source their drugs, and the factor that make them more likely to engage a contract manufacturing organization (CMO).

  • CMO executives who must have a deep understanding of the NME approvals landscape to make strategic planning and investment decisions.
  • Sourcing and procurement executives who must understand crucial components of the supply base in order to make decisions about supplier selection and management.
  • Pharmaceutical and biotech companies evaluating potential licensing deals as a licensor or licensee.
  • Investors that need a deeper understanding of the market to identify and value potential investment targets.

Reasons to Buy
  • Overview of novel drugs (NMEs) approved by FDA 2014-2018
  • Detailed analysis of dose outsourcing likelihood by: licensing status, market cap, molecule type
  • Spotlight on licensing deals and outsourcing propensity
  • Detailed methodology explains use of data from the The publisher Pharma Intelligence Center databases

Table of Contents

1 Table of Contents

2 List of Tables

3 List of Figures

4 Executive Summary

5 Introduction

6 Licensing of New Molecular Entities Approved 2014-2018

7 Timing of Licensing Deals
7.1 Chronology of Licensing and Outsourcing

8 Outsourcing Propensity by Source of NME
8.1 Product Source and Outsourcing Propensity by Market Cap

9 Trends by Molecule Type
9.1 In-Licensing by Molecule Type
9.1.1 Spotlight On: Cell and Gene Therapies
9.2 Dose Manufacture by Molecule Type

10 Company Analysis

11 What It Means

12 Notes on Methodology

13 Appendix
13.1 Bibliography
13.2 Primary Research - Key Opinion Leaders Featured in This Report
13.3 About the Authors
13.4 Contact Information
13.5 Disclaimer

List of Tables

Table 1: Breakdown of Approvals 2014-2018 by Company Market Cap Band

List of Figures

Figure 1: Source of NMEs Approved 2014-2018
Figure 2: Source of NMEs Approved 2014-2018, by Year
Figure 3: Status of Approved In-Licensed NMEs at Time of Licensing Deal, 2014-2018
Figure 4: Status of Approved In-Licensed NMEs at Time of Licensing Deal, 2014-2018, by Year
Figure 5: Chronology of Licensing and Outsourcing for NMEs Approved 2014-2018
Figure 6: Source of Dose-Outsourced NMEs (Approved 2014-2018)
Figure 7: Dose Form Manufacture by Source of NMEs Approved 2014-2018
Figure 8: Dose Outsourcing of NMEs (Approved 2014-2018) by Company Market Cap and NME Source
Figure 9: NME Source by Molecule Type
Figure 10: Dose Manufacture of In-licensed NMEs Approved 2014-2018, by Molecule Type
Figure 11: Top 9 Companies by NME Approvals 2014-2018, by NME Source

Companies Mentioned

A selection of companies mentioned in this report includes:

  • Amgen Inc
  • Astellas Pharma
  • AstraZeneca Plc
  • Bristol-Myers Squibb
  • Cabaret Biotech
  • ClearView Healthcare Partners
  • CSL
  • Cytovant Sciences
  • Eli Lilly and Co
  • Gilead Sciences
  • GlaxoSmithKline
  • Johnson & Johnson
  • Legend Biotech